Predicting disease progression after regional therapy for in-transit melanoma.

ABSTRACT:

Importance

Although approximately 30% to 50% of patients experience a complete response after regional chemotherapy for in-transit melanoma, a subset of patients will develop rapidly progressive disease. In the current era of an expanding armamentarium, including both regional and systemic options for treating advanced melanoma, identifying perioperative factors that predict disease progression may obviate unnecessary morbidity associated with regional therapy and avoid delays in systemic therapy.

Objective

To identify patient-related clinical and pathological variables, as well as procedural factors, that correlate with disease progression.

Design

Using a prospectively maintained database, we identified patients who either underwent first-time melphalan-based isolate

SUBMITTER: Lidsky ME 

PROVIDER: S-EPMC5161094 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature